312 related articles for article (PubMed ID: 19823051)
1. Efficacy of human papillomavirus vaccines: a systematic quantitative review.
Medeiros LR; Rosa DD; da Rosa MI; Bozzetti MC; Zanini RR
Int J Gynecol Cancer; 2009 Oct; 19(7):1166-76. PubMed ID: 19823051
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review.
Gonçalves AK; Cobucci RN; Rodrigues HM; de Melo AG; Giraldo PC
Braz J Infect Dis; 2014; 18(6):651-9. PubMed ID: 24780368
[TBL] [Abstract][Full Text] [Related]
5. A review of clinical trials of human papillomavirus prophylactic vaccines.
Schiller JT; Castellsagué X; Garland SM
Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
[TBL] [Abstract][Full Text] [Related]
6. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
[TBL] [Abstract][Full Text] [Related]
7. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18.
Frederick PJ; Huh WK;
Expert Rev Anticancer Ther; 2008 May; 8(5):701-5. PubMed ID: 18471043
[TBL] [Abstract][Full Text] [Related]
9. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Schiller JT; Castellsagué X; Villa LL; Hildesheim A
Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.
Arbyn M; Xu L
Expert Rev Vaccines; 2018 Dec; 17(12):1085-1091. PubMed ID: 30495978
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus.
Mavundza EJ; Wiyeh AB; Mahasha PW; Halle-Ekane G; Wiysonge CS
Hum Vaccin Immunother; 2020; 16(2):426-435. PubMed ID: 31448991
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.
Miltz A; Price H; Shahmanesh M; Copas A; Gilson R
PLoS One; 2014; 9(3):e90348. PubMed ID: 24595046
[TBL] [Abstract][Full Text] [Related]
13. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus and vaccination in cervical cancer.
Wang KL
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):352-62. PubMed ID: 18182340
[TBL] [Abstract][Full Text] [Related]
15. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
Harper DM; Franco EL; Wheeler CM; Moscicki AB; Romanowski B; Roteli-Martins CM; Jenkins D; Schuind A; Costa Clemens SA; Dubin G;
Lancet; 2006 Apr; 367(9518):1247-55. PubMed ID: 16631880
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group
N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
Yoshikawa H; Ebihara K; Tanaka Y; Noda K
Cancer Sci; 2013 Apr; 104(4):465-72. PubMed ID: 23331518
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
McIntosh J; Sturpe DA; Khanna N
J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
[TBL] [Abstract][Full Text] [Related]
19. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
20. [Diseases caused by human papilloma viruses].
Zollner U; Schwarz TF
Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]